A Potential Best-in-Class Therapy for Alzheimer’s Disease
ProMIS’ lead therapeutic product candidate, PMN310, is a monoclonal therapeutic antibody designed for the treatment of Alzheimer’s disease (AD). By selectively targeting the toxic oligomers of amyloid-beta (Aβ), PMN310 may possess the qualities necessary to potentially be “best-in-class”, if approved, with a possibly more favorable clinical safety and efficacy profile over other amyloid-directed antibody therapeutics currently in clinical development.
Three Forms of Amyloid Protein
- Monomers - Simple strings of amino acids that play a role in normal brain health.
- Oligomers - Small clumps of molecules that consist of several monomer units.
- Plaque - Insoluble, solid deposits of amyloid (similar to plaque in arteries) that can build up over time. Usually present, but does not appear to play a significant role in disease progression.
The Right Target
Only misfolded oligomers are toxic, which can lead to neuronal death and synaptic loss that causes AD-related cognitive decline. Studies indicate that safe and effective antibody therapies for AD will be those that selectively target and bind only to misfolded oligomers while avoiding any binding to monomers and/or plaque forms of amyloid.